Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design


  • Org Study ID: CXB/2019/US
  • Secondary ID: N/A
  • NTC ID: NCT03988309
  • Sponsor: Pacific Edge Limited


To evaluate the clinical utility associated with the integration of Cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (UC) without compromising detection of UC.


Randomised two arm pragmatic clinical study to be conducted at multiple sites in US and Canada. The trial will recruit hematuria subjects, presenting to qualified sites (academic, community), who are being evaluated for urothelial carcinoma (UC). Up to 100 consecutive eligible subjects will be recruited per site.

  • Overall Status
  • Start Date
    September 11, 2019
  • Phase
    Not Applicable
  • Study Type


Primary Outcome 1 - Measure: To measure the change in cystoscopy procedure use count between control and test arms when Cxbladder is used in the evaluation

Primary Outcome 1 - Timeframe: The outcome measure will be assessed by 6 months after trial completion.


  • Hematuria
  • Urothelial Carcinoma


Inclusion Criteria :
Patient is undergoing investigation of recent confirmed hematuria (by either flexible or rigid cystoscopy/TURBT), including hematuria subjects referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.

- Able to provide a voided urine sample of the required minimum volume

- Able to give written consent

- Able and willing to comply with study requirements

- Aged 18 years or older
Exclusion Criteria
Prior history of bladder malignancy, prostate or renal cell carcinoma

- Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection,

- History of glomerulonephritis, nephrosis or other renal inflammatory disorders, recent history of pyelonephritis

- Previous alkylating based chemotherapy

- Pregnancy

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Tony Lough, PhD

Role: Study Chair

Affiliation: Pacific Edge Pty Ltd

Overall Contact

Name: Tony Lough, PhD

Phone: 2146458764



Facility Status Contact
Facility: Institute of Urology, USC Norris Comprehensive Cancer Center
Los Angeles, California 90089
United States
Status: Recruiting Contact: Contact
Ileana Aldana
323-865-0702 261
Facility: Accellacare
Chicago, Illinois 60515
United States
Status: Recruiting Contact: Principal Investigator
Sumeet Bhanvadia
717-531-5930 69308
Facility: University of Minnesota, Department of Urology
Minneapolis, Minnesota 55455
United States
Status: Recruiting Contact: Contact
Lori Clausen
843-449-1010 56366
Facility: Division of urology, Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania 17033-0850
United States
Status: Recruiting Contact: Principal Investigator
Amit Patel
Facility: Carolina Urologic Research Center
Myrtle Beach, South Carolina 29572
United States
Status: Recruiting Contact: Contact
Tracy M Daye-Groves
Facility: Department of Urology,Vanderbilt University
Nashville, Tennessee 37232
United States
Status: Recruiting Contact: Principal Investigator
Christopher Warlick
Facility: UT Southwestern Medical Center
Dallas, Texas 75390
United States
Status: Recruiting Contact: Contact
Kathy Lehman
Facility: UTHSA - Mays Cancer Center
San Antonio, Texas 78229
United States
Status: Recruiting Contact: Principal Investigator
Jay Raman
Facility: The prostate centre- Diamond Health care centre
Vancouver, British Columbia V5Z1M9
Status: Recruiting Contact: Contact
Jessica Richardson, RN
Facility: London Health Sciences Centre Victoria Hospital
London, Ontario N6A5W9
Status: Recruiting Contact: Principal Investigator
Neal Shore, MD